CPA
DGX icon

Capital Performance Advisors’s Quest Diagnostics DGX Stock Holding History

Capital Performance Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-111
Closed -$17.2K – 835
2024
Q3 		$17.2K Buy
+111
New +$16.6K 0.01% 656

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital Performance Advisors's DGX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Quest Diagnostics (DGX) in Q4 2024, closing a stake of 111 shares — an estimated $17.2K sold.

Capital Performance Advisors first reported a position in DGX in Q3 2024 and held it in 1 quarter. The position peaked at $17.2K in Q3 2024. 895 funds tracked by Wall St. Rank hold DGX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Quest Diagnostics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 111 Quest Diagnostics shares in Q4 2024, an estimated $17.2K.
  • Capital Performance Advisors first reported a position in Quest Diagnostics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Quest Diagnostics position peaked at $17.2K in Q3 2024.
  • 895 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.